Recent News

• 05.17.2025 - Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
• 05.15.2025 - Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
• 05.15.2025 - Atara Biotherapeutics Announces Pricing of $16 Million Offering
• 05.05.2025 - Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
• 03.07.2025 - Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - 8-K Current report
• 05.15.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.15.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 8-K Current report
• 05.06.2025 - 8-K Current report
• 05.06.2025 - EX-99.1 EX-99.1
• 04.28.2025 - DEF 14A Other definitive proxy statements
• 04.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material